Foghorn Therapeutics Inc (FHTX)

May 21, 2026

Foghorn Therapeutics (FHTX) Posts Record Q1 2026 — EPS $-0.29 Blows Past EstimatesLive Trade Sharing - Newser

May 21, 2026

May 18, 2026

Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN

May 18, 2026

May 16, 2026

FHTX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

May 16, 2026

May 15, 2026

BVF entities disclose shares, 6.05M pre‑funded warrants in Foghorn (FHTX) - Stock Titan

May 15, 2026

May 15, 2026

EDGAR Filing Documents for 0001628280-25-014475 - SEC.gov

May 15, 2026

May 14, 2026

[SCHEDULE 13G/A] Foghorn Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan

May 14, 2026

May 13, 2026

Foghorn Therapeutics discloses new EP300 degradation inducers - BioWorld News

May 13, 2026

May 12, 2026

Foghorn Therapeutics schedules trio of investor events to spotlight oncology developments - Traders Union

May 12, 2026

May 12, 2026

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - Investing News Network

May 12, 2026

May 11, 2026

Foghorn Therapeutics Inc. (FHTX) may report negative earnings: Know the trend ahead of Q1 release - MSN

May 11, 2026

May 11, 2026

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) First-Quarter Report - simplywall.st

May 11, 2026

May 11, 2026

The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance

May 11, 2026

May 10, 2026

FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

May 10, 2026

May 09, 2026

Foghorn Therapeutics Inc. (FHTX) reports Q1 loss, lags revenue estimates - MSN

May 09, 2026

May 08, 2026

What Foghorn Therapeutics (FHTX) is doing to win in its industry | Q4 2025: Earnings UnderperformSocial Momentum Signals - newser.com

May 08, 2026

May 07, 2026

Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 07, 2026

May 07, 2026

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update - Investing News Network

May 07, 2026

May 07, 2026

Number of shareholders of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView

May 07, 2026

May 07, 2026

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 07, 2026

May 07, 2026

Foghorn Therapeutics Highlights Q1 Progress in Oncology Pipeline - TipRanks

May 07, 2026

May 07, 2026

Foghorn Therapeutics Inc. 1Q 2026: Revenue $3.3M, EPS $(0.29) — 10-Q Summary - TradingView

May 07, 2026

May 07, 2026

Foghorn says lead lung cancer trial stays on track, funded into 2028 - Stock Titan

May 07, 2026

May 07, 2026

Foghorn Therapeutics (NASDAQ: FHTX) trims expenses, raises $50M in Q1 2026 - Stock Titan

May 07, 2026

May 07, 2026

Foghorn Therapeutics (Nasdaq: FHTX) details Q1 2026 results and oncology pipeline - Stock Titan

May 07, 2026

May 06, 2026

FMR LLC reports 11.6% ownership in Foghorn Therapeutics (NASDAQ: FHTX) - Stock Titan

May 06, 2026

May 06, 2026

Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance

May 06, 2026

May 06, 2026

The quiet positioning of Foghorn Therapeutics (FHTX) nobody discusses (Market Focus) 2026-05-06Bullish Pattern - Newser

May 06, 2026

Apr 30, 2026

[ARS] Foghorn Therapeutics Inc. SEC Filing - Stock Titan

Apr 30, 2026

Apr 30, 2026

Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan

Apr 30, 2026

Apr 30, 2026

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 30, 2026

Apr 28, 2026

Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9%Time to Sell? - MarketBeat

Apr 28, 2026

Apr 27, 2026

Stifel reiterates Foghorn Therapeutics stock rating on AACR data By Investing.com - Investing.com Australia

Apr 27, 2026

Apr 27, 2026

Stifel Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo

Apr 27, 2026

Apr 27, 2026

Stifel reiterates Foghorn Therapeutics stock rating on AACR data - Investing.com

Apr 27, 2026

Apr 23, 2026

Should I sell Foghorn Therapeutics (FHTX) stock today | Q4 2025: Earnings UnderperformExpert Momentum Signals - Xã Châu Thành

Apr 23, 2026

Apr 22, 2026

H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com India

Apr 22, 2026

Apr 22, 2026

H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy - Investing.com

Apr 22, 2026

Apr 22, 2026

Foghorn presents preclinical data for cancer drug candidates By Investing.com - Investing.com South Africa

Apr 22, 2026

Apr 21, 2026

FHTX Unveils Promising Preclinical Data at AACR Annual Meeting - GuruFocus

Apr 21, 2026

Apr 21, 2026

Foghorn presents preclinical data for cancer drug candidates - Investing.com

Apr 21, 2026

Apr 21, 2026

Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR - TipRanks

Apr 21, 2026

Apr 21, 2026

Foghorn Therapeutics presents new preclinical data on SMARCA2 inhibitor FHD-909 and targeted degrader programs - Traders Union

Apr 21, 2026

Apr 21, 2026

Foghorn Therapeutics Presents New Preclinical Data for - GlobeNewswire

Apr 21, 2026

Apr 21, 2026

Foghorn Therapeutics (Nasdaq: FHTX) showcases broad preclinical cancer data and cash runway outlook - Stock Titan

Apr 21, 2026